Pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, Kilitch Drugs (India) has informed that the meeting of the Board of Directors of the Company will be held on Monday, 27th May, 2024 to consider and approve the audited Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended 31st March, 2024. Pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 read with SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018 read with Circular No. LIST/COMP/01/2019-20 dated 2nd April, 2019 issued by BSE and Circular Reference no. NSE/CML/2019/11 dated 2nd April, 2019 issued by NSE and Company’s code of conduct for Prevention of Insider Trading, the Trading Window has been closed with effect from 1st April, 2024 and will re-open 48 hours after said financial results are disclosed to the Stock Exchanges.
The above information is a part of company’s filings submitted to BSE.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1797.80 |
Dr. Reddys Lab | 1213.90 |
Cipla | 1486.30 |
Lupin | 2069.95 |
Zydus Lifesciences | 948.70 |
View more.. |